<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OPP</journal-id>
<journal-id journal-id-type="hwp">spopp</journal-id>
<journal-id journal-id-type="nlm-ta">J Oncol Pharm Pract</journal-id>
<journal-title>Journal of Oncology Pharmacy Practice</journal-title>
<issn pub-type="ppub">1078-1552</issn>
<issn pub-type="epub">1477-092X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1078155211428998</article-id>
<article-id pub-id-type="publisher-id">10.1177_1078155211428998</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Tran</surname><given-names>L</given-names></name>
</contrib>
<aff id="aff1-1078155211428998">Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Huitema</surname><given-names>ADR</given-names></name>
</contrib>
<aff id="aff2-1078155211428998">Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Vogel</surname><given-names>WV</given-names></name>
</contrib>
<aff id="aff3-1078155211428998">Department of Nuclear Medicine, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Beijnen</surname><given-names>JH</given-names></name>
<xref ref-type="corresp" rid="corresp1-1078155211428998"/>
</contrib>
<aff id="aff4-1078155211428998">Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands; Faculty of Pharmaceutical Sciences, Department of Biomedical Analysis, Section of Drug Toxicology, Utrecht University, Utrecht, The Netherlands</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Baars</surname><given-names>JW</given-names></name>
</contrib>
<aff id="aff5-1078155211428998">Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1078155211428998">JH Beijnen, Department of Pharmacy &amp; Pharmacology, Slotervaart Hospital, P.O. Box 90440, 1006 BK Amsterdam, The Netherlands. Email: <email>Jos.Beijnen@slz.nl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>4</issue>
<fpage>417</fpage>
<lpage>420</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Radioimmunotherapy has emerged as a treatment modality for patients with CD20 positive B-cell non-Hodgkin’s lymphoma (NHL). Prior to administration of a therapeutic dose, confirmation of uptake of the radiolabeled compound in tumor locations and calculation of an appropriate dose can be performed using a diagnostic dose and subsequent imaging. We report the case of a 69-year-old male with a relapsed mantle cell lymphoma scheduled for radioimmunotherapy, where diagnostic imaging with 131-I labeled rituximab revealed unexpected new insights with implications for treatment. Persistence of the mantle cell lymphoma in a lymph node in the left arm was demonstrated by an 18-F fluorodeoxyglucose scan. However, a scan after a diagnostic dose of 131-I labeled rituximab did not show any uptake of the tracer, even though subsequent cytological analysis unequivocally confirmed a CD20 positive B-cell population in the lesion. The administration of a therapeutic dose of 131-I labeled rituximab was therefore cancelled. We here discuss the mechanisms that may explain lack of targeting in a proven CD20-positive lymphoma and provide recommendations for further studies.</p>
</abstract>
<kwd-group>
<kwd>Mantle cell lymphoma</kwd>
<kwd>131-I labeled rituximab</kwd>
<kwd>radio-immunotherapy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1078155211428998"><title>Background</title>
<p>Radiolabeled monoclonal antibodies have been used as a radioimmunotherapeutic agent for patients with NHL.<sup><xref ref-type="bibr" rid="bibr1-1078155211428998">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr4-1078155211428998">4</xref></sup> Radioimmunotherapy offers targeted irradiation to CD20-positive cells and promotes cytotoxic activity by the crossfire-effect to neighboring tumor cells with none or insufficient antigen expression.<sup><xref ref-type="bibr" rid="bibr5-1078155211428998">5</xref></sup> Encouraging results have been reported about this targeted therapy strategy, but this case report illustrates a patient with a relapsed mantle cell lymphoma with a vital and CD20-positive lesion who did not show any tumor uptake of 131-I labeled rituximab. We here report the results of our investigations and provide recommendations for further studies.</p>
</sec>
<sec id="sec2-1078155211428998"><title>Case representation</title>
<p>The patient was a 69-year-old male with a relapsed mantle cell lymphoma. At the time of diagnosis, histological and flow cytometric analysis had confirmed the presence of CD20 positive B-cells. The patient relapsed after several rituximab containing treatment regimens, in a lymph node in the left elbow and in the left axilla. Remission induction treatment was given in a 4-weekly schedule of three cycles R-PECC (rituximab 375 mg/m<sup>2</sup> intravenously on day 1, prednisone 40 mg/m<sup>2</sup> orally on days 1−6, etoposide 100 mg/m<sup>2</sup> orally on days 2−6, CCNU (lomustine) 40 mg/m<sup>2</sup> orally on day 1, and chlorambucil 8 mg/m<sup>2</sup> orally on days 2−6). A 18-F FDG scan was performed after the second cycle, which showed a complete metabolic remission of the lymphadenopathy in the left axilla, but a metabolically active localization of the lymph node in the left elbow indicating a persistent vital tumor site. The patient was considered to be in partial response. After written informed consent was obtained, the patient was scheduled for a consolidation treatment with 131-I labeled rituximab in a clinical trial approved by our medical ethical committee.</p>
<p>The patient received a pretreatment dose of 2.5 mg/kg unlabeled rituximab, followed by a diagnostic dose of 185 MBq 131-I labeled rituximab to perform dosimetry prior to radioimmunotherapy. Whole body scans after 24 h and 48 h showed circulation of the tracer with no obvious clearance. No accumulation of 131-I labeled rituximab could be detected in the tumor lesion in the left elbow (<xref ref-type="fig" rid="fig1-1078155211428998">Figure 1</xref>). Due to this finding a beneficial effect of radioimmunotherapy was considered unlikely, and thus, administration of the therapeutic dose was cancelled.
<fig id="fig1-1078155211428998" position="float"><label>Figure 1.</label><caption><p>Imaging of 131-I radiolabeled rituximab. (A) Whole body scan from anterior 48 h p.i. shows the bio-distribution of the antibody. (B) Scan of the arms from posterior show no accumulation in the vital and CD20 positive lymphoma location, which can be seen on the 18-F FDG-PET scan (C).</p></caption><graphic xlink:href="10.1177_1078155211428998-fig1.tif"/>
</fig></p>
<p>Cytological biopsy of the tumor location in the left elbow was performed. Flow cytometric analysis showed a population of CD20-positive B-cells, and therefore the lack of targeting of the antibody remained unexplained. At the time of administration of the diagnostic dose, the patient had a rituximab serum concentration of 20.2 µg/mL, measured using an enzyme-linked immuno sorbent assay (ELISA). Further treatment of the patient consisted of local radiation therapy of the left elbow and axilla. Hereafter, the patient was in complete remission, 8 months to date.</p>
</sec>
<sec id="sec3-1078155211428998" sec-type="discussion"><title>Discussion</title>
<p>Radioimmunotherapy has emerged as a promising treatment modality in patients with a CD20-positive NHL. Encouraging results have been reported for both non-myeloablative and myeloablative treatment regimens.<sup><xref ref-type="bibr" rid="bibr1-1078155211428998">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr4-1078155211428998">4</xref></sup> Our case illustrates a patient scheduled for radioimmunotherapy as consolidation therapy after remission induction treatment, who unexpectedly showed no targeting of 131-I labeled rituximab in a remaining proven vital and CD20-positive lesion.</p>
<p>This case shows that several factors have to be taken into account for the optimal use of radioimmunotherapy with radiolabeled anti-CD20 monoclonal antibodies in patients with NHL who are pretreated with rituximab-containing chemotherapy. These factors are the heterogeneity of CD20 antigen expression, the method by which CD20 antigen positivity has been determined (e.g. flow cytometry, immunochemistry), prior regimens, especially prior doses of rituximab that can saturate the CD20 antigen, possible change of the CD20 antigen by pretreatment of rituximab, change of configuration of the monoclonal antibody by radiolabeling, tumor load, and the variability of the pharmacokinetics of rituximab.</p>
<p>The CD20 antigen expression, as assessed by flow cytometric analysis, is heterogeneous between and within different lymphoma subtypes and might even be different in tumor localizations. These differences may correlate with clinical responses to rituximab and to radioimmunotherapy.<sup><xref ref-type="bibr" rid="bibr6-1078155211428998">6</xref>,<xref ref-type="bibr" rid="bibr7-1078155211428998">7</xref></sup> The method at which the CD20 expression has been determined has to be taken into consideration. Apart from this, in our patient, the positive CD20 antigen expression of the NHL was determined by flow cytometry and was strongly positive.</p>
<p>The pretreatment of rituximab prior to the administration of radioimmunotherapy with 131-I labeled rituximab can also be a critical factor for the success of this treatment. Both preclinical and clinical data support the value of pretreatment with unlabeled rituximab to improve tumor targeting and extend the residence time of the radioimmunoconjugates in the circulation. However, a too high dose of unlabeled rituximab may compete with the 131-I labeled rituximab and compromise on the selective uptake of 131-I rituximab in tumor sites.<sup><xref ref-type="bibr" rid="bibr8-1078155211428998">8</xref></sup> Our patient had a relapse after administration of several rituximab-containing regimens. Gopal et al. evaluated the impact of prior rituximab on the binding of a secondary administration of anti-CD20 monoclonal antibodies.<sup><xref ref-type="bibr" rid="bibr9-1078155211428998">9</xref></sup> The authors found that, in vitro and in animal studies, sequential use of anti-CD20 monoclonal antibodies resulted in almost complete inhibition of binding of the second anti-CD20 monoclonal antibody. This suggests that high circulating rituximab concentrations may impair the clinical efficacy of anti-CD20 radioimmunotherapy. Clinical studies have shown the efficacy of radioimmunotherapy in rituximab refractory patients with measurable serum rituximab levels prior to treatment.<sup><xref ref-type="bibr" rid="bibr10-1078155211428998">10</xref></sup> However, results from other studies had suggested that therapeutic responses were caused by non-targeted radiation, induced by radioimmunotherapy.<sup><xref ref-type="bibr" rid="bibr11-1078155211428998">11</xref>,<xref ref-type="bibr" rid="bibr12-1078155211428998">12</xref></sup> At the time of administration of the diagnostic dose of 131-I labeled rituximab, the patient had a rituximab serum concentration of 20.2 µg/mL corresponding to a circulating amount of rituximab of approximately 100 mg. It is questionable if 131-I labeled rituximab would be efficacious as consolidation therapy for patients who have received extensive pre-treatment with rituximab. Thus, more studies are required to estimate the optimal time point for radio-immunotherapy. Additionally, previous studies have shown the deterioration of the binding capacity, the immunoreactivity, of rituximab to the CD20 antigen after radio-labeling.<sup><xref ref-type="bibr" rid="bibr13-1078155211428998">13</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr15-1078155211428998">15</xref></sup> A reduced immunoreactivity can cause less binding to the CD20 antigen. However, quality control of the radioconjugate showed a product with high preservation of its integrity.<sup><xref ref-type="bibr" rid="bibr14-1078155211428998">14</xref></sup></p>
<p>Another possible explanation for the lack of binding could be a change in the configuration of the CD20 antigen. It is known that therapies may lead to selection of treatment-resistant subpopulations with specific characteristics that differ from the original tumor cell population.<sup><xref ref-type="bibr" rid="bibr16-1078155211428998">16</xref>,<xref ref-type="bibr" rid="bibr17-1078155211428998">17</xref></sup> The remaining lesion in the presented patient was the only lesion not responding to the R-PECC induction treatment. In retrospect, it is impossible to determine differences in the CD20 epitope in the remaining lesion before and after induction remission treatment or between the remaining lesion and lesions that did respond to the treatment. Therefore, unexpected (changes in) tumor behavior with respect to antibody binding may occur and remain unexplained in future cases as well.</p>
<p>However, radiolabeled rituximab can be used for diagnostic imaging in order to select patients with proper binding, who might profit from addition of rituximab to their chemotherapeutic regimens. In addition, by administering a diagnostic dose of 131-I labeled rituximab the biodistribution of the radiolabeled compound can be observed in a whole body approach. Based on the results of this procedure, we decided not to administer a therapeutic dose of 131-I labeled rituximab to the patient presented here. Similar procedures have already been included in the treatment strategy for 90-Y ibritumomab tiuxetan and 131-I tositumomab to exclude patients with unfavorable biodistribution,<sup><xref ref-type="bibr" rid="bibr18-1078155211428998">18</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr20-1078155211428998">20</xref></sup> and we conclude that this approach is mandatory for 131-I labeled rituximab as well.</p>
<p>A downside of 131-I labeled rituximab as a diagnostic imaging agent is that it is limited to γ-camera imaging, with relatively poor image resolution and sub-optimal quantification. Recent developments have allowed the preparation of 124-I labeled rituximab for positron emission tomography (PET) as has been proposed before,<sup><xref ref-type="bibr" rid="bibr21-1078155211428998">21</xref></sup> for diagnostic imaging with superior sensitivity and quantification.</p>
<p>We conclude that the radiolabeled rituximab as a radiodiagnostic imaging agent can have an additive value in the selection of patients with CD20-positive NHL for treatment with CD20 targeted monoclonal antibodies.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-1078155211428998"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RI</given-names></name><name><surname>Kaminski</surname><given-names>MS</given-names></name><name><surname>Wahl</surname><given-names>RL</given-names></name><name><surname>Knox</surname><given-names>SJ</given-names></name><name><surname>Zelenetz</surname><given-names>AD</given-names></name><name><surname>Vose</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas</article-title>. <source>J Clin Oncol</source> <year>2005</year>; <volume>23</volume>(<issue>30</issue>): <fpage>7565</fpage>–<lpage>7573</lpage>.</citation></ref>
<ref id="bibr2-1078155211428998"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Witzig</surname><given-names>TE</given-names></name></person-group>. <article-title>Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radio-immunotherapy for non-Hodgkin's lymphoma</article-title>. <source>Semin Oncol</source> <year>2003</year>; <volume>30</volume>(<issue>6, Suppl 17</issue>): <fpage>11</fpage>–<lpage>16</lpage>.</citation></ref>
<ref id="bibr3-1078155211428998"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Press</surname><given-names>OW</given-names></name><name><surname>Eary</surname><given-names>JF</given-names></name><name><surname>Gooley</surname><given-names>T</given-names></name><name><surname>Gopal</surname><given-names>AK</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Rajendran</surname><given-names>JG</given-names></name><etal/></person-group>. <article-title>A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas</article-title>. <source>Blood</source> <year>2000</year>; <volume>96</volume>(<issue>9</issue>): <fpage>2934</fpage>–<lpage>2942</lpage>.</citation></ref>
<ref id="bibr4-1078155211428998"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaminski</surname><given-names>MS</given-names></name><name><surname>Tuck</surname><given-names>M</given-names></name><name><surname>Estes</surname><given-names>J</given-names></name><name><surname>Kolstad</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>CW</given-names></name><name><surname>Zasadny</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>131I-tositumomab therapy as initial treatment for follicular lymphoma</article-title>. <source>N Engl J Med</source> <year>2005</year>; <volume>352</volume>(<issue>5</issue>): <fpage>441</fpage>–<lpage>449</lpage>.</citation></ref>
<ref id="bibr5-1078155211428998"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maloney</surname><given-names>DG</given-names></name><name><surname>Grillo-Lopez</surname><given-names>AJ</given-names></name><name><surname>White</surname><given-names>CA</given-names></name><name><surname>Bodkin</surname><given-names>D</given-names></name><name><surname>Schilder</surname><given-names>RJ</given-names></name><name><surname>Neidhart</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma</article-title>. <source>Blood</source> <year>1997</year>; <volume>90</volume>(<issue>6</issue>): <fpage>2188</fpage>–<lpage>2195</lpage>.</citation></ref>
<ref id="bibr6-1078155211428998"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>NA</given-names></name><name><surname>Boyle</surname><given-names>M</given-names></name><name><surname>Bashashati</surname><given-names>A</given-names></name><name><surname>Leach</surname><given-names>S</given-names></name><name><surname>Brooks-Wilson</surname><given-names>A</given-names></name><name><surname>Sehn</surname><given-names>LH</given-names></name><etal/></person-group>. <article-title>Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival</article-title>. <source>Blood</source> <year>2009</year>; <volume>113</volume>(<issue>16</issue>): <fpage>3773</fpage>–<lpage>3780</lpage>.</citation></ref>
<ref id="bibr7-1078155211428998"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dayde</surname><given-names>D</given-names></name><name><surname>Ternant</surname><given-names>D</given-names></name><name><surname>Ohresser</surname><given-names>M</given-names></name><name><surname>Lerondel</surname><given-names>S</given-names></name><name><surname>Pesnel</surname><given-names>S</given-names></name><name><surname>Watier</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20</article-title>. <source>Blood</source> <year>2009</year>; <volume>113</volume>(<issue>16</issue>): <fpage>3765</fpage>–<lpage>3772</lpage>.</citation></ref>
<ref id="bibr8-1078155211428998"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharkey</surname><given-names>RM</given-names></name><name><surname>Press</surname><given-names>OW</given-names></name><name><surname>Goldenberg</surname><given-names>DM</given-names></name></person-group>. <article-title>A re-examination of radio-immunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radio-antibody therapy</article-title>. <source>Blood</source> <year>2009</year>; <volume>113</volume>(<issue>17</issue>): <fpage>3891</fpage>–<lpage>3895</lpage>.</citation></ref>
<ref id="bibr9-1078155211428998"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gopal</surname><given-names>AK</given-names></name><name><surname>Press</surname><given-names>OW</given-names></name><name><surname>Wilbur</surname><given-names>SM</given-names></name><name><surname>Maloney</surname><given-names>DG</given-names></name><name><surname>Pagel</surname><given-names>JM</given-names></name></person-group>. <article-title>Rituximab blocks binding of radio-labeled anti-CD20 antibodies (Ab) but not radio-labeled anti-CD45 Ab</article-title>. <source>Blood</source> <year>2008</year>; <volume>112</volume>(<issue>3</issue>): <fpage>830</fpage>–<lpage>835</lpage>.</citation></ref>
<ref id="bibr10-1078155211428998"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Illidge</surname><given-names>TM</given-names></name><name><surname>Bayne</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>NS</given-names></name><name><surname>Chilton</surname><given-names>S</given-names></name><name><surname>Cragg</surname><given-names>MS</given-names></name><name><surname>Glennie</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radio-immunotherapy</article-title>. <source>Blood</source> <year>2009</year>; <volume>113</volume>(<issue>7</issue>): <fpage>1412</fpage>–<lpage>1421</lpage>.</citation></ref>
<ref id="bibr11-1078155211428998"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iagaru</surname><given-names>A</given-names></name><name><surname>Gambhir</surname><given-names>SS</given-names></name><name><surname>Goris</surname><given-names>ML</given-names></name></person-group>. <article-title>90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging</article-title>. <source>J Nucl Med</source> <year>2008</year>; <volume>49</volume>(<issue>11</issue>): <fpage>1809</fpage>–<lpage>1812</lpage>.</citation></ref>
<ref id="bibr12-1078155211428998"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>PS</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>Pieslor</surname><given-names>P</given-names></name><name><surname>Molina</surname><given-names>A</given-names></name><name><surname>Aussie</surname><given-names>J</given-names></name><name><surname>Foster</surname><given-names>P</given-names></name></person-group>. <article-title>The role of imaging with 111In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: results from a Zevalin imaging registry</article-title>. <source>J Nucl Med</source> <year>2005</year>; <volume>46</volume>(<issue>11</issue>): <fpage>1812</fpage>–<lpage>1818</lpage>.</citation></ref>
<ref id="bibr13-1078155211428998"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>GW</given-names></name><name><surname>Klok</surname><given-names>RP</given-names></name><name><surname>Gebbinck</surname><given-names>JW</given-names></name><name><surname>ter Linden</surname><given-names>T</given-names></name><name><surname>van Dongen</surname><given-names>GA</given-names></name><name><surname>Molthoff</surname><given-names>CF</given-names></name></person-group>. <article-title>Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN</article-title>. <source>J Nucl Med</source> <year>2001</year>; <volume>42</volume>(<issue>3</issue>): <fpage>509</fpage>–<lpage>519</lpage>.</citation></ref>
<ref id="bibr14-1078155211428998"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>L</given-names></name><name><surname>Baars</surname><given-names>JW</given-names></name><name><surname>Maessen</surname><given-names>HJ</given-names></name><name><surname>Hoefnagel</surname><given-names>CA</given-names></name><name><surname>Beijnen</surname><given-names>JH</given-names></name><name><surname>Huitema</surname><given-names>AD</given-names></name></person-group>. <article-title>A simple and safe method for 131I radio-labeling of rituximab for myeloablative high-dose radioimmunotherapy</article-title>. <source>Cancer Biother Radiopharm</source> <year>2009</year>; <volume>24</volume>(<issue>1</issue>): <fpage>103</fpage>–<lpage>110</lpage>.</citation></ref>
<ref id="bibr15-1078155211428998"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schaffland</surname><given-names>AO</given-names></name><name><surname>Buchegger</surname><given-names>F</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Antonescu</surname><given-names>C</given-names></name><name><surname>Paschoud</surname><given-names>C</given-names></name><name><surname>Grannavel</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>131I-rituximab: relationship between immunoreactivity and specific activity</article-title>. <source>J Nucl Med</source> <year>2004</year>; <volume>45</volume>(<issue>10</issue>): <fpage>1784</fpage>–<lpage>1790</lpage>.</citation></ref>
<ref id="bibr16-1078155211428998"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jilani</surname><given-names>I</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name><name><surname>Manshuri</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>DA</given-names></name><name><surname>Thomazy</surname><given-names>VA</given-names></name><name><surname>Imam</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia</article-title>. <source>Blood</source> <year>2003</year>; <volume>102</volume>(<issue>10</issue>): <fpage>3514</fpage>–<lpage>3520</lpage>.</citation></ref>
<ref id="bibr17-1078155211428998"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cragg</surname><given-names>MS</given-names></name><name><surname>Bayne</surname><given-names>MC</given-names></name><name><surname>Illidge</surname><given-names>TM</given-names></name><name><surname>Valerius</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>PW</given-names></name><name><surname>Glennie</surname><given-names>MJ</given-names></name></person-group>. <article-title>Apparent modulation of CD20 by rituximab: an alternative explanation</article-title>. <source>Blood</source> <year>2004</year>; <volume>103</volume>(<issue>10</issue>): <fpage>3989</fpage>–<lpage>3990</lpage>.</citation></ref>
<ref id="bibr18-1078155211428998"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiseman</surname><given-names>GA</given-names></name><name><surname>Leigh</surname><given-names>B</given-names></name><name><surname>Erwin</surname><given-names>WD</given-names></name><name><surname>Lamonica</surname><given-names>D</given-names></name><name><surname>Kornmehl</surname><given-names>E</given-names></name><name><surname>Spies</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Radiation dosimetry results for Zevalin radio-immunotherapy of rituximab-refractory non-Hodgkin lymphoma</article-title>. <source>Cancer</source> <year>2002</year> <volume>94</volume>(<issue>4 Suppl</issue>): <fpage>1349</fpage>–<lpage>1357</lpage>.</citation></ref>
<ref id="bibr19-1078155211428998"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajendran</surname><given-names>JG</given-names></name><name><surname>Fisher</surname><given-names>DR</given-names></name><name><surname>Gopal</surname><given-names>AK</given-names></name><name><surname>Durack</surname><given-names>LD</given-names></name><name><surname>Press</surname><given-names>OW</given-names></name><name><surname>Eary</surname><given-names>JF</given-names></name></person-group>. <article-title>High-dose (131)I-tositumomab (anti-CD20) radio-immunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes</article-title>. <source>J Nucl Med</source> <year>2004</year>; <volume>45</volume>(<issue>6</issue>): <fpage>1059</fpage>–<lpage>1064</lpage>.</citation></ref>
<ref id="bibr20-1078155211428998"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morschhauser</surname><given-names>F</given-names></name><name><surname>Illidge</surname><given-names>T</given-names></name><name><surname>Huglo</surname><given-names>D</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name><name><surname>Paganelli</surname><given-names>G</given-names></name><name><surname>Zinzani</surname><given-names>PL</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation</article-title>. <source>Blood</source> <year>2007</year>; <volume>110</volume>(<issue>1</issue>): <fpage>54</fpage>–<lpage>58</lpage>.</citation></ref>
<ref id="bibr21-1078155211428998"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verel</surname><given-names>I</given-names></name><name><surname>Visser</surname><given-names>GW</given-names></name><name><surname>Vosjan</surname><given-names>MJ</given-names></name><name><surname>Finn</surname><given-names>R</given-names></name><name><surname>Boellaard</surname><given-names>R</given-names></name><name><surname>van Dongen</surname><given-names>GA</given-names></name></person-group>. <article-title>High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radio-immunotherapy</article-title>. <source>Eur J Nucl Med Mol Imaging</source> <year>2004</year>; <volume>31</volume>(<issue>12</issue>): <fpage>1645</fpage>–<lpage>1652</lpage>.</citation></ref>
</ref-list>
</back>
</article>